Merck opens Virginia plant to support UNICEF deal for HPV vaccines
A construction project built around expanding the vaccine manufacturing capabilities at a Merck site in Elkton, VA, has been completed. The upgrades will support the company’s human papillomavirus vaccine, Gardasil 9, once it gains review and approval from regulators.
About 150 new jobs have been added to the site, as the location is now 120,000 square feet larger.
“As we continue to increase production of our HPV vaccines, we are prioritizing access in countries with a high burden of disease, including countries eligible for support from Gavi and UNICEF,” Priya Agrawal, global lead for HPV Vaccines at Merck, said. “Through our long-term agreement with UNICEF, we plan to provide 91.5 million doses of our HPV vaccines for use in Gavi-supported countries from 2021-2025, and we have offered additional doses beyond that agreement as needed to help meet growing demand.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.